Genome Publications
https://doi.org/10.61096/978-81-990998-7-6_15

Chapter 15

Pharmacokinetic and Pharmacodynamic Modeling: PBPK, Dose Optimization and Patient Stratification

Dr. Kolanedi. Anupama Priyadarshini
Associate professor, Sims college of pharmacy, Guntur.

DhulipallaCurie
Associate Professor, SIMS College of Pharmacy, Guntur

Dr. Kiran Gerapati
Professor, Department of Pharmacology, Chennupati Indo American school of Pharmacy, Palnadu, Andhra Pradesh

Abstract: Pharmacokinetic (PK) and pharmacodynamic (PD) modeling form the quantitative backbone of translational pharmacology, linking drug exposure to therapeutic response and toxicity. In silico pharmacokinetic–pharmacodynamic (PK/PD) modeling has evolved from empirical compartmental models to sophisticated physiologically based pharmacokinetic (PBPK) simulations that integrate anatomical, physiological, biochemical, and molecular parameters. These computational frameworks allow prediction of drug absorption, distribution, metabolism, and excretion (ADME) across diverse populations and disease states. PBPK models, augmented by AI-driven analytics and multi-omics data, now inform dose optimization, drug–drug interaction assessment, and regulatory submissions. Coupling PK/PD models with pharmacogenomics enables precise patient stratification, minimizing adverse effects and maximizing therapeutic benefit. This chapter explores theoretical foundations, computational workflows, and translational applications of PK/PD modeling in drug design and development. Comparative analysis of empirical versus mechanistic modeling approaches, integration with QSAR and ADMET predictions, and incorporation of population variability underscore its role in precision therapeutics. Current trends in AI-enhanced modeling, real-time Bayesian adaptive dosing, and virtual clinical trials signal a paradigm shift toward individualized pharmacotherapy. The chapter concludes with discussions on model validation, regulatory acceptance, and future challenges in bridging data-driven and mechanistic modeling for holistic drug development.

Keywords: Pharmacokinetics, Pharmacodynamics, PBPK modeling, Dose optimization, Patient stratification.

Citation: Kolanedi. Anupama Priyadarshini, DhulipallaCurie, Kiran Gerapati. Pharmacokinetic and Pharmacodynamic Modeling: PBPK, Dose Optimization and Patient Stratification. *Comprehensive Approaches in Computer-Aided Drug Design: QSAR, Docking, Screening, Homology, Pharmacophore and AI-Driven Insights.* Genome Publication. 2025; Pp187-196.
https://doi.org/10.61096/978-81-990998-7-6_15

15.0 INTRODUCTION

Pharmacokinetic and Pharmacodynamic Modeling

Pharmacokinetics (PK) and phar macodynamics (PD) are central pillars of drug development and rational therapeutic design, providing a mathematical framework to quantify drug behavior within the body and its corresponding biological effects. Pharmacokinetics delineates the journey of a drug through absorption, distribution, metabolism, and excretion (ADME), while pharmacodynamics quantifies the biochemical and physiological consequences of drug–target interaction, often summarized as the concentration–effect relationship. The synergy between these domains forms the PK/PD paradigm a bidirectional interface that connects systemic exposure to pharmacological response, toxicity, and therapeutic outcome. Historically, PK/PD modeling originated from simple one- and two-compartment models developed during the mid-20th century, where plasma concentration–time curves were analyzed using linear differential equations. These empirical models, while foundational, were limited by their inability to generalize across populations or physiological conditions. The emergence of physiologically based pharmacokinetic (PBPK) modeling transformed this landscape by embedding drug behavior within mechanistic representations of organ systems, tissue compartments, and blood flow parameters derived from human or animal physiology [1]. PBPK models thus transitioned from descriptive to predictive tools, capable of simulating drug kinetics across species, age groups, and pathological states.

Contemporary computational advances have further expanded PK/PD capabilities through integration with machine learning, Bayesian inference, and systems pharmacology approaches. These enable the dynamic incorporation of patient-specific data such as genomics, metabolomics, or comorbidity profiles into individualized dosing models. The convergence of these methodologies underpins precision pharmacometrics, where quantitative models support regulatory decisions, trial simulations, and therapeutic optimization. This chapter systematically dissects theoretical principles, model architectures, and translational workflows underpinning modern PK/PD analysis, emphasizing the evolving role of PBPK and AI-enhanced patient stratification in next-generation drug design.

15.1 Theoretical Foundations of PK and PD Modeling

Pharmacokinetic modeling traditionally employs compartmental systems that approximate the body as interconnected compartments, each representing a homogenous distribution space. The one-compartment model assumes instantaneous equilibrium between plasma and tissue, suitable for drugs with rapid distribution and simple elimination kinetics. In contrast, multi-compartment models capture more complex absorption and distribution phenomena by introducing central and peripheral compartments, each characterized by unique rate constants (k_{12}, k_{21}, k_{10}). These models form the backbone of clinical PK analysis, enabling estimation of clearance (CL), volume of distribution (Vd), and half-life (t½) [2]. Pharmacodynamic modeling complements PK analysis by describing the temporal relationship between drug concentration and pharmacological effect. Classical PD models, such as the Emax or sigmoid Emax models, capture the saturation of receptor-mediated responses. These are mathematically expressed as $E = (Emax \times C^n) / (EC50^n + C^n)$, where Emax denotes maximal effect, EC50 represents concentration achieving 50% effect, and n is the Hill coefficient reflecting cooperativity [3]. Such equations enable quantification of potency and efficacy, critical for defining therapeutic windows and dosing intervals.

Beyond empirical representations, mechanistic PK/PD models integrate molecular target dynamics, receptor occupancy, signal transduction, and feedback regulation. These models, often grounded in systems biology, reveal non-linearities arising from saturable metabolism, transporter

competition, or delayed pharmacological responses. For example, indirect response models incorporate turnover rates of endogenous substances modulated by drug action, providing insights into delayed efficacy phenomena observed in corticosteroids or kinase inhibitors [4]. Emerging hybrid frameworks merge statistical and mechanistic approaches, using nonlinear mixed-effects modeling (NLME) or population PK (popPK) analysis to capture interindividual variability while preserving physiological realism. These models are instrumental in dose optimization, extrapolation across demographics, and virtual population simulations. The fusion of mechanistic insight with empirical flexibility represents a defining evolution in PK/PD modeling theory.

15.2 Physiologically Based Pharmacokinetic (PBPK) Modeling: Principles and Architecture

Physiologically based pharmacokinetic (PBPK) models extend beyond traditional compartmental frameworks by explicitly representing human anatomy and physiology through interconnected tissue and organ modules. Each compartment such as liver, kidney, muscle, fat, or brain is described by parameters including organ volume, blood flow rate, tissue–plasma partition coefficients, and metabolic enzyme expression [5]. PBPK modeling thereby provides a mechanistic, species-independent framework capable of predicting drug kinetics from in vitro and preclinical data. The core structure of PBPK models relies on mass balance differential equations defining drug movement across compartments. For each organ, the rate of change in drug concentration is determined by arterial inflow, venous outflow, and metabolic clearance terms. Key physiological parameters are obtained from literature databases or population surveys, while compound-specific inputs such as lipophilicity, plasma protein binding, or intrinsic clearance are derived from in vitro experiments. Software platforms such as Simcyp, PK-Sim, GastroPlus, and Berkeley Madonna provide standardized workflows for model construction, parameterization, and simulation [6].

A notable strength of PBPK modeling is its ability to extrapolate across populations, including pediatrics, geriatrics, and patients with hepatic or renal impairment. By adjusting organ sizes, blood flows, and enzyme ontogeny profiles, models simulate age-dependent or disease-induced alterations in pharmacokinetics. Furthermore, PBPK frameworks are invaluable for predicting drug–drug interactions (DDIs) by incorporating enzyme inhibition, induction, or transporter competition. This predictive capability supports regulatory decision-making and reduces the need for extensive clinical DDI trials [7]. Recent advances integrate genomic and proteomic data to reflect interindividual variability in CYP450 expression and transporter abundance, ushering in population-specific PBPK models. Moreover, hybrid PBPK–PD constructs extend mechanistic modeling to downstream pharmacodynamic outcomes, linking tissue exposure to therapeutic or toxic endpoints. This mechanistic transparency and adaptability render PBPK modeling a cornerstone of modern model-informed drug development (MIDD).

15.3 Computational Workflows and Software Tools in PBPK Modeling

The construction of PBPK models follows a modular computational workflow comprising parameter definition, model coding, calibration, and validation. Initial steps involve gathering physiological data organ weights, tissue volumes, blood flow rates from established references such as ICRP or ICRU tables. Drug-specific parameters including permeability coefficients, solubility, pKa, logP, and metabolic clearance are derived from in vitro microsomal assays or predicted using QSAR/ADMET software [8]. The integration of these datasets into computational frameworks enables real-time simulation of plasma and tissue concentration–time profiles. Modern PBPK software such as PK-Sim (part of the Open Systems Pharmacology Suite) provides a user-friendly interface for

model construction, parameter fitting, and sensitivity analysis. It enables the creation of virtual populations reflecting demographic diversity. Simcyp Simulator, widely adopted in industry, supports clinical trial simulation, DDI risk assessment, and pediatric scaling under regulatory guidance [9]. GastroPlus, developed by Simulations Plus, incorporates advanced absorption models accounting for gut physiology, first-pass metabolism, and transporter-mediated uptake. Meanwhile, open-source tools such as mrgsolve (R-based) and Berkeley Madonna cater to research and educational applications, offering flexibility for differential equation-based simulations.

Calibration of PBPK models is typically performed through iterative fitting to observed pharmacokinetic data using nonlinear regression or Bayesian algorithms. Global sensitivity analysis (GSA) identifies parameters exerting maximal influence on model outputs, guiding experimental prioritization. Subsequent validation employs independent datasets or cross-species scaling to confirm predictive reliability. Regulatory agencies such as the FDA and EMA now accept PBPK submissions for DDI prediction and first-in-human (FIH) dose estimation, reflecting the growing confidence in computational pharmacokinetics [10]. AI integration further refines PBPK workflows by automating parameter optimization, identifying latent correlations, and improving model generalizability. The convergence of mechanistic modeling and machine learning marks a key step toward predictive, adaptive, and population-aware pharmacometric frameworks.

15.4 Linking Pharmacokinetic and Pharmacodynamic Models: Mechanistic Integration

The integration of pharmacokinetic (PK) and pharmacodynamic (PD) models forms the foundation for quantitatively linking drug exposure to pharmacological response, a concept that underlies dose optimization, efficacy prediction, and toxicity minimization. In its simplest form, PK/PD integration follows a sequential modeling approach, where the output of a PK model typically plasma or tissue concentration is used as the input driving a PD effect model. This framework enables characterization of the concentration–effect relationship, providing insight into time delays between systemic exposure and observed biological outcomes [11]. Mechanistic linkage models can be categorized into direct and indirect response models. In direct models, effect is instantaneously related to concentration, assuming equilibrium between plasma and receptor sites. Conversely, indirect models capture delayed effects arising from physiological or biochemical processes such as receptor binding kinetics, enzyme turnover, or signal transduction cascades. These are represented mathematically by differential equations incorporating synthesis (kin) and degradation (kout) rate constants for the response variable. For example, corticosteroid suppression of cortisol secretion exemplifies an indirect inhibitory model where drug action modulates an endogenous mediator [12].

A particularly sophisticated approach involves effect compartment modeling, where an additional theoretical compartment represents the biophase i.e., the site of drug action. This accounts for hysteresis phenomena in PK/PD plots where effect lags behind plasma concentration due to slow distribution or receptor interaction kinetics. Integration of receptor occupancy models, derived from molecular docking or kinetic binding data, further refines PD linkage by quantifying target engagement as a function of concentration and affinity (Kd) [13]. In modern systems pharmacology, PK/PD integration transcends empirical fitting to encompass mechanistic cascade modeling, incorporating downstream biomarker dynamics, feedback loops, and multi-scale interactions. Hybrid PBPK–PD models thus simulate not only systemic exposure but also local tissue pharmacodynamics, capturing heterogeneity across organs or disease states. For instance, models integrating hepatic PBPK and PD response have been applied to optimize dosing for statins and tyrosine kinase inhibitors, accounting for local metabolic saturation and receptor-mediated feedback [14]. This mechanistic depth enhances

translational confidence by reproducing clinical dose–response relationships and interindividual variability.

Such integrative frameworks underpin model-informed drug development (MIDD), endorsed by regulatory bodies, where virtual clinical trials and quantitative pharmacology guide dose selection, trial design, and labeling decisions. The fusion of PK and PD domains represents a major step toward rational, predictive, and personalized pharmacotherapy.

15.5 Dose Optimization and Individualized Therapy

The ultimate goal of PK/PD modeling is to enable rational dose optimization, ensuring therapeutic efficacy while minimizing toxicity. Traditional dose-finding approaches relied on empirical titration during clinical trials, often limited by interindividual variability and ethical constraints. In contrast, model-based dosing strategies leverage quantitative simulations to identify optimal regimens under diverse physiological and pathological scenarios [15]. Model-informed precision dosing (MIPD) employs individual-specific parameters such as age, body weight, organ function, and genetic polymorphisms to tailor dosage. Population PK (popPK) models, implemented through nonlinear mixed-effects analysis (e.g., NONMEM, Monolix, or Phoenix NLME), quantify variability across individuals and isolate covariates influencing clearance or distribution. Bayesian forecasting subsequently refines these estimates using therapeutic drug monitoring (TDM) data, enabling adaptive dosing in real time [16]. This framework is particularly valuable for narrow-therapeutic-index drugs such as vancomycin, tacrolimus, and warfarin.

PBPK modeling contributes to dose optimization by simulating first-in-human (FIH) and special-population scenarios pediatrics, geriatrics, pregnancy, or hepatic/renal impairment where empirical data are scarce. For example, pediatric PBPK models scale adult pharmacokinetics using physiological ontogeny functions for enzyme maturation and organ growth, guiding ethical and safe pediatric trials [17]. Similarly, in oncology, PK/PD models integrating tumor growth inhibition dynamics with exposure metrics (AUC, Cmax) have refined scheduling of cytotoxic agents and immune checkpoint inhibitors. The rise of AI-enhanced dose prediction introduces data-driven complementarity to mechanistic modeling. Machine learning algorithms trained on clinical datasets identify nonlinear relationships between covariates and exposure or response, outperforming classical regression in high-dimensional spaces. Neural network–augmented PBPK models can dynamically recalibrate dose predictions based on evolving patient parameters such as hepatic function or concurrent medications [18].

Ultimately, individualized therapy derived from these integrative models supports precision medicine, reducing trial-and-error prescribing. By combining mechanistic transparency, statistical inference, and data-driven adaptability, PK/PD-guided dose optimization represents a cornerstone of 21st-century therapeutics.

15.6 Patient Stratification: Genomic, Physiological, and AI-Based Approaches

Patient stratification dividing populations into subgroups with distinct pharmacological responses is essential for precision drug development. Variability in drug exposure and response stems from genetic, physiological, and environmental factors that influence pharmacokinetics and pharmacodynamics. Modeling frameworks integrating these variables provide a predictive basis for personalized dosing strategies and risk assessment [19]. Pharmacogenomics plays a pivotal role in stratification, revealing how genetic polymorphisms in drug-metabolizing enzymes, transporters, or receptors affect drug behavior. Variants in CYP2D6, CYP3A4, or SLCO1B1 genes, for instance,

profoundly alter clearance of antidepressants, statins, and anticancer agents. Incorporating allele frequencies into population PBPK models enables prediction of exposure differences between metabolizer phenotypes poor, intermediate, extensive, or ultra-rapid metabolizers thereby informing genotype-based dosing [20]. The Clinical Pharmacogenetics Implementation Consortium (CPIC) and regulatory agencies increasingly advocate for model-supported genotype-guided prescribing.

Beyond genomics, physiological stratification accounts for age, sex, body composition, and disease state. For example, changes in plasma protein binding in liver disease or altered glomerular filtration in chronic kidney disease significantly modify drug distribution and elimination. PBPK models parameterized with pathophysiological data simulate these conditions, aiding therapeutic optimization in vulnerable populations [21]. Artificial intelligence extends stratification through multimodal data integration, combining clinical records, omics profiles, imaging, and wearable sensor data to cluster patients by latent pharmacological phenotypes. Unsupervised learning techniques, such as hierarchical clustering or variational autoencoders, identify subgroups with distinct PK/PD patterns, while reinforcement learning algorithms propose individualized dosing adjustments based on real-time feedback [22].

These AI-driven stratification approaches herald a paradigm shift from population averages to dynamic individualization, where each patient's digital twin can simulate drug exposure, response, and toxicity risk before actual administration. Integrating such frameworks with electronic health records and regulatory pharmacometrics pipelines accelerates translation into clinical practice.

15.7 Model Validation, Qualification, and Regulatory Acceptance

For pharmacometric models to influence decision-making in drug development and clinical care, validation and regulatory qualification are indispensable. Validation ensures that model predictions are credible, reproducible, and physiologically plausible. This process encompasses structural verification, parameter sensitivity analysis, and external validation against independent datasets [23]. Regulatory authorities, including the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and Pharmaceuticals and Medical Devices Agency (PMDA), have established frameworks for model-informed drug development (MIDD). These frameworks outline standards for submitting PBPK and PK/PD models in support of DDI risk assessment, bioequivalence waivers, and first-in-human dose selection. The FDA's guidance on PBPK submissions (2020) specifies expectations for model documentation, qualification datasets, and predictive performance metrics such as fold-error and visual predictive checks [24].

Model qualification extends beyond validation, representing a formal recognition that a model is fit for a specific regulatory purpose. For example, Simcyp's qualified DDI models have been accepted for predicting CYP3A4- and P-gp–mediated interactions without additional in vivo studies. Similarly, population PK models are increasingly employed to justify dosing regimens in labeling, particularly for biologics and orphan drugs where clinical trial data are limited [25]. A critical element in regulatory acceptance is transparency documenting model assumptions, data sources, and uncertainty quantification. Sensitivity and uncertainty analyses, including Monte Carlo simulations, evaluate robustness under parameter variability. Standardized reporting templates (e.g., Model Master File, EMA PBPK template) promote harmonization across submissions.

Emerging trends involve model lifecycle management, where models are continuously updated as new data emerge, transitioning from static validation to dynamic qualification. Collaborative initiatives such as the IQ Consortium and Open Systems Pharmacology foster best

practices for reproducibility and open science, bridging industry, academia, and regulators in advancing computational pharmacology.

Table 15.1 Comparison of Compartmental, Population, and PBPK Models

Feature	Compartmental Models	Population PK (popPK) Models	Physiologically Based PK (PBPK) Models
Model Type	Empirical, simplified representation of body compartments	Statistical-mixed effects models capturing interindividual variability	Mechanistic, physiology-driven multi-organ representation
Data Requirements	Clinical plasma concentration data	Clinical data from heterogeneous populations	In vitro data, physiological parameters, enzyme/transporter kinetics
Physiological Realism	Low – limited biological meaning	Moderate – variability captured statistically	High – explicit anatomy, blood flow, and enzyme distribution
Predictive Capability	Limited extrapolation	Good within studied populations	Excellent across species, populations, and disease states
Applications	Initial dose estimation, classical PK studies	Covariate analysis, dose adjustment, variability quantification	DDI prediction, pediatric/adult scaling, regulatory submissions
Software Tools	WinNonlin, MATLAB	NONMEM, Monolix, Phoenix NLME	PK-Sim, Simcyp, GastroPlus
Regulatory Acceptance	Limited	Moderate (labeling justification)	High (FDA/EMA MIDD programs)
Advantages	Simplicity, low computational cost	Handles variability and covariates	Mechanistic insight, translational applicability
Limitations	Lack of physiological context	Requires large datasets	Complex, parameter-intensive, computationally demanding



Figure 1: Framework of PBPK–PD Modeling and Dose Optimization Pipeline

15.8 Future Perspectives: Virtual Trials, Digital Twins, and AI-Driven Pharmacometrics

The convergence of PBPK modeling, AI analytics, and real-world data is propelling pharmacometrics into the era of virtual clinical trials and digital twins. Virtual trials leverage validated PBPK–PD models to simulate population responses under varying dosing scenarios, reducing dependence on costly or ethically constrained human studies. Such simulations have been successfully applied in predicting pediatric dosing, rare-disease pharmacokinetics, and population variability in vaccine pharmacodynamics [26]. The emerging concept of the patient digital twin a dynamic, individualized computational replica embodies the ultimate vision of precision therapeutics. Digital twins integrate genomics, physiology, lifestyle, and real-time biosensor data to continuously simulate drug exposure and response, enabling adaptive therapy management. In oncology, hybrid PK/PD–AI platforms are being developed to predict tumor response trajectories and guide combination regimens, while in infectious diseases, adaptive Bayesian frameworks optimize antibiotic stewardship [27].

Advancements in machine learning–accelerated PBPK modeling promise greater scalability and interpretability. Deep learning surrogates can approximate computationally intensive simulations, facilitating high-throughput sensitivity analysis and uncertainty quantification. Integration with multi-scale systems biology further bridges molecular interactions with organism-level outcomes, aligning pharmacometrics with holistic systems pharmacology paradigms. Sustainability and ethics also define future directions. The shift toward green computation optimizing code efficiency, using cloud-based GPU clusters powered by renewable energy reflects the environmental responsibility of digital pharmacology. Additionally, transparent AI governance ensures that data-driven dosing recommendations remain explainable and equitable across populations [28].

In summary, the future of PK/PD modeling lies in synergistic integration uniting mechanistic understanding, data-driven intelligence, and ethical transparency. As virtual trials and digital twins transition from concept to clinical utility, model-informed precision medicine will redefine the landscape of drug discovery, development, and personalized therapy.

REFERENCES

1. Rowland M, Tozer TN. *Clinical Pharmacokinetics and Pharmacodynamics: Concepts and Applications.* 5th ed. Philadelphia: Wolters Kluwer; 2021.
2. Gabrielsson J, Weiner D. *Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and Applications.* 5th ed. CRC Press; 2016.
3. Holford NHG, Sheiner LB. Understanding the dose-effect relationship: Clinical application of pharmacokinetic-pharmacodynamic models. *Clin Pharmacokinet.* 1981;6(6):429–53.
4. Jusko WJ, Ko HC. Physiologic indirect response models characterize diverse types of pharmacodynamic effects. *J Pharm Sci.* 1994;83(3):304–10.
5. Jones HM et al. Physiologically based pharmacokinetic modeling in drug discovery and development: A pharmaceutical industry perspective. *Clin Pharmacol Ther.* 2015;97(3):247–62.
6. Willmann S et al. Development of a physiologically based pharmacokinetic model for PK-Sim. *J Pharmacokinet Pharmacodyn.* 2003;30(5):277–310.
7. Sager JE et al. Physiologically based pharmacokinetic modeling for regulatory applications. *Clin Pharmacol Ther.* 2015;97(5):498–514.
8. Yang J, Liederer BM, Pool WF. Use of in vitro data in PBPK modeling. *AAPS J.* 2019;21(3):1–14.
9. Jamei M. Recent advances in development and application of PBPK models: A transition from academic curiosity to regulatory acceptance. *CPT Pharmacometrics Syst Pharmacol.* 2020;9(4):211–24.
10. Food and Drug Administration (FDA). *Physiologically Based Pharmacokinetic Analyses Format and Content Guidance for Industry.* 2020.
11. Danhof M et al. Mechanism-based pharmacokinetic–pharmacodynamic modeling. *Clin Pharmacokinet.* 2008;47(9):605–26.
12. Mager DE, Jusko WJ. General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. *J Pharmacokinet Pharmacodyn.* 2001;28(6):507–32.
13. Gabrielsson J, Weiner D. Receptor-based models and hysteresis in pharmacodynamics. *Eur J Pharm Sci.* 2000;9(1):1–12.
14. Zhao P, Zhang L, Grillo JA et al. Applications of PBPK modeling in regulatory submissions. *Clin Pharmacol Ther.* 2011;89(2):259–67.
15. Holford N. Pharmacokinetic–pharmacodynamic modeling of drug effects. *Br J Clin Pharmacol.* 2018;84(9):1866–72.
16. Ette EI, Williams PJ. Population pharmacokinetics I: Background, concepts, and models. *Ann Pharmacother.* 2004;38(10):1702–6.
17. Maharaj AR, Edginton AN. Physiologically based pharmacokinetic modeling and simulation in pediatric drug development. *CPT Pharmacometrics Syst Pharmacol.* 2014;3(11):e150.
18. Xu Y et al. AI-assisted pharmacokinetic modeling for individualized dosing. *Front Pharmacol.* 2023;14:1192331.
19. Shah RR, Smith RL. Pharmacogenomics in drug regulation. *Nat Rev Drug Discov.* 2015;14(7):463–76.
20. Barbarino JM et al. Integrating pharmacogenomics into PBPK modeling: CYP2D6 case studies. *Clin Transl Sci.* 2021;14(6):2310–23.
21. Edginton AN, Theil FP. Incorporating disease-specific pathophysiology into PBPK models. *Clin Pharmacokinet.* 2020;59(5):495–507.
22. Choi Y, Lee J, Kim S. Deep learning–based patient stratification using multimodal data integration. *Patterns.* 2022;3(5):100520.

23. Rostami-Hodjegan A. Physiologically based pharmacokinetics joined with in vitro–in vivo extrapolation: An emerging strategy for drug development. *Annu Rev Pharmacol Toxicol.* 2012;52:89–111.
24. EMA. *Guideline on the qualification and reporting of PBPK modeling and simulation.* 2021.
25. Wagner C, Zhao P, Pan Y. Application of PBPK modeling in regulatory submissions: An update. *CPT Pharmacometrics Syst Pharmacol.* 2023;12(2):134–45.
26. Yoon M, Clewell HJ. Virtual clinical trials in PBPK modeling. *Regul Toxicol Pharmacol.* 2017;88:315–26.
27. Shimizu R, Arai T, et al. Digital twin–based pharmacometrics for oncology. *Front Pharmacol.* 2024;15:1378815.
28. Helms PJ et al. Ethical and sustainable computation in digital pharmacology. *Drug Discov Today.* 2025;30(1):45–57.